Liver Viscoelastic Changes and Biomarkers for Cancer Invasion
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsNatalie J. Torok, Ovijit Chaudhuri, Weiguo Fan
Life of this patent
Estimating the term…
Abstract
Methods of prognosis, diagnosis, therapy selection, drug screening, and monitoring treatment of hepatocellular carcinoma (HCC) are provided. Increased viscoelasticity of liver tissue is associated with HCC progression; therefore, measurements of viscoelasticity of liver tissue can be used to provide an indication of the risk of HCC progression in a patient. In addition, animal models of hydrodynamically induced HCC and methods of using such animal models for research and development of therapeutics for treating HCC are also provided.
Claims26
A method of diagnosing and treating hepatocellular carcinoma (HCC) in a patient, the method comprising:
- measuring viscoelasticity of liver tissue from the patient, wherein increased viscoelasticity of the liver tissue of the patient compared to reference value ranges for viscoelasticity of liver tissue from a control subject indicates that the patient is at risk of developing the HCC or has a positive diagnosis for the HCC;
- and
- treating the patient for the HCC, if the patient has a positive diagnosis for the HCC based on the measured viscoelasticity of the liver tissue.
3-4. (canceled)
6-8. (canceled)
A method of generating a non-human animal model of non-alcoholic steatohepatitis with hydrodynamically induced hepatocellular carcinoma (HCC), the method comprising:
- administering an advanced glycation end-product to the non-human animal, wherein viscoelasticity of liver tissue increases in the non-human animal.
(canceled)
(canceled)
A method of treating a subject for hepatocellular carcinoma (HCC), the method comprising administering a therapeutically effective amount of an advanced glycation end product (AGE) inhibitor, a crosslink breaker that cleaves crosslinks formed by an AGE, or a combination thereof to the subject.
24-28. (canceled)
A method of treating a subject for hepatocellular carcinoma (HCC), the method comprising administering a vector comprising a promoter operably linked to a nucleotide sequence comprising a coding sequence encoding AGER1 to the subject, wherein a therapeutically effective amount of the AGER1 is expressed in vivo in the subject.
33-45. (canceled)
Dependencies are inferred from the claim text.